PD-L1 positivity was defined as ≥ 1% on tumor or stroma cells using the 22C3 antihuman PD-1 antibody (Merck & Co., Kenilworth, NJ, USA) and was identified in nearly 60% of the screened patients. Here, PDCD1 is linked to neoplasm.